FORT WASHINGTON, PA—(Marketwired – September 26, 2016) – Myeloproliferative Neoplasms (MPN) are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers — Myelofibrosis, Essential Thrombocythemia (ET), and Polycythemia vera (PV) — affect approximately 13,000, 134,000, and 148,000 patients in the United States, respectively.
To provide clinicians with the most up–to–date and comprehensive treatment recommendations, the National Comprehensive Cancer NetworkÂ® (NCCNÂ®) today published the NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®) for MPN to specifically outline diagnosis, treatment, and supportive care strategies for Myelofibrosis. Myelofibrosis is a type of MPN that is the result — in most cases — of one of three genetic mutations within the JAK2 signaling pathway. Comprehensive recommendations for the management of ET and PV will be included in the subsequent versions of the NCCN GuidelinesÂ® for MPN.
NCCN Guidelines document evidence–based consensus–driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive care services that are most likely to lead to optimal outcomes.
“The management of MPNs has been variable in the past and largely driven by review articles and individual opinions. The NCCN Guidelines Panel for MPN hopes these inaugural Guidelines will help leverage the evidence base in MPN care for clear, well–informed, treatment guidelines to hopefully improve quality of care and provide better outcomes for patients with MPN,” said Ruben A. Mesa, MD, FACP, Mayo Clinic Cancer Center, Chair of the NCCN Guidelines Panel for MPN.
Dr. Mesa will present the new NCCN Guidelines in an educational setting during the NCCN 11th Annual Congress: Hematologic Malignanciesâ¢ on Friday, September 30, in a session titled, “Myeloprofilerative Neoplasms and Myelofibrosis: Evolving Management.” To register, visit NCCN.org/HEM.
With the publication of the NCCN Guidelines for MPN, the library of NCCN Guidelines now includes 63 clinical guidelines detailing sequential management decisions and interventions that currently apply to 97 percent of cancers affecting people in the United States, as well as cancer prevention, detection and risk reduction, and age–related recommendations.
Available free–of–charge to registered users of NCCN.org and through the Virtual Library of NCCN Guidelines Mobile Apps, NCCN Guidelines help oncologists make the major clinical decisions encountered in managing their patients by providing ready access to synthesized information. The NCCN Guidelines provide recommendations for appropriate care for most, but not all patients; however, all individual patient circumstances must be considered when applying these recommendations.
To access the NCCN Guidelines for MPN, visit NCCN.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer NetworkÂ® (NCCNÂ®), a not–for–profit alliance of 27 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high–quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision–makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana–Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes–Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt–Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
 Metha J, Wang H, Iqbal SU, Mesa R, Epidemiology of myeloproliferative neoplasms in the United States, Leuk Lymph 2014;55:595–600.
The following files are available for download: